Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Cancer Diagnosis & Prognosis|July 4, 2024
Gleason Pattern 5 May Be a Prognostic Factor in Radium-223 TreatmentMitsuhisa Nishimoto, Kazutoshi Fujita, Aritoshi Ri, et al.
International Journal of Clinical Oncology|October 1, 2024
Real-world outcomes in patients with metastatic castration-resistant prostate cancer beyond progression after upfront androgen receptor signaling inhibitorYutaka Yamamoto, Saizo Fujimoto, Mamoru Hashimoto, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 14, 2025
Comparison of Oncological Outcomes of Conventional Androgen Deprivation Therapy (ADT) and ADT Plus Androgen Receptor Signaling Inhibitor in Older Patients With Metastatic Castration-Sensitive Prostate CancerYutaka Yamamoto, Saizo Fujimoto, Mamoru Hashimoto, et al.
Scientific Reports|July 2, 2025
Comparison of genetic mutations in bladder cancers that arose following radiotherapy for prostate cancer with those in primary bladder cancersShogo Adomi, Kazuko Sakai, Yurie Kura, et al.
Urologic Oncology|December 28, 2025
Comparison of prostate-specific antigen kinetics between androgen receptor signaling inhibitor doublet therapy and androgen receptor signaling inhibitor with docetaxel triplet therapy in patients with metastatic castration-sensitive prostate cancerTsuyoshi Morita, Yutaka Yamamoto, Saizo Fujimoto, et al.
The Prostate|January 16, 2025
Screening for Predictive Factors of Efficacy of Second-Generation Androgen Receptor Axis-Targeted Agents in Patients With High-Risk Metastatic Hormone-Sensitive Prostate CancerTakashi Ueda, Keita Hayakawa, Go Horiguchi, et al.
Anti-Cancer Drugs|September 6, 2021
Disseminated intravascular coagulation induced by pazopanib following combination therapy of nivolumab plus ipilimumab in a patient with metastatic renal cell carcinomaMamoru Hashimoto, Takahito Nakayama, Saizo Fujimoto, et al.
Translational Andrology and Urology|August 25, 2021
Higher neutrophil-to-lymphocyte ratio after the first cycle of the first-line chemotherapy is associated with poor cancer specific survival of upper urinary tract carcinoma patientsMamoru Hashimoto, Kazutoshi Fujita, Takahito Nakayama, et al.
Cancer Science|December 4, 2024
Comparative analysis of gut microbiota in hormone-sensitive and castration-resistant prostate cancer in Japanese menSaizo Fujimoto, Koji Hatano, Eri Banno, et al.
The Prostate|March 15, 2026
The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With First-Line ARPI TherapyTakeshi Tsutsumi, Shogo Yamazaki, Takuya Matsuda, et al.
Pageof 3